Norikazu Masuda

29.7k total citations · 10 hit papers
389 papers, 14.0k citations indexed

About

Norikazu Masuda is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Norikazu Masuda has authored 389 papers receiving a total of 14.0k indexed citations (citations by other indexed papers that have themselves been cited), including 316 papers in Oncology, 162 papers in Pulmonary and Respiratory Medicine and 145 papers in Cancer Research. Recurrent topics in Norikazu Masuda's work include HER2/EGFR in Cancer Research (149 papers), Cancer Treatment and Pharmacology (138 papers) and Breast Cancer Treatment Studies (130 papers). Norikazu Masuda is often cited by papers focused on HER2/EGFR in Cancer Research (149 papers), Cancer Treatment and Pharmacology (138 papers) and Breast Cancer Treatment Studies (130 papers). Norikazu Masuda collaborates with scholars based in Japan, United States and South Korea. Norikazu Masuda's co-authors include Seock‐Ah Im, Hiroji Iwata, Pierfranco Conté, Binghe Xu, Mark E. Robson, Suzette Delaloge, Elżbieta Senkus, Nadine Tung, Anne Armstrong and Susan M. Domchek and has published in prestigious journals such as New England Journal of Medicine, Nucleic Acids Research and Journal of Clinical Oncology.

In The Last Decade

Norikazu Masuda

364 papers receiving 13.7k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation

2017 2.2k citations Mark E. Robson, Seock‐Ah Im et al. New England Journal of Medicine profile →
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

2016 1.2k citations Seock‐Ah Im, Norikazu Masuda et al. profile →
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

2017 1.1k citations Masakazu Toi, Kenichi Inoue et al. Journal of Clinical Oncology profile →
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer

2018 777 citations Seock‐Ah Im, Norikazu Masuda et al. New England Journal of Medicine profile →
Extended Clavien-Dindo classification of surgical complications: Japan Clinical Oncology Group postoperative complications criteria

2015 603 citations Norikazu Masuda et al. profile →
Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer

2022 594 citations Javier Cortés, Hope S. Rugo et al. New England Journal of Medicine profile →
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

2019 590 citations Masakazu Toi, Kenichi Inoue et al. profile →
Analysis of chemical modification of RNA from formalin-fixed samples and optimization of molecular biology applications for such samples

1999 534 citations Norikazu Masuda et al. profile →
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer

2019 497 citations Mark E. Robson, Nadine Tung et al. profile →
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2− ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study

2022 114 citations Hope S. Rugo, Seock‐Ah Im et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Norikazu Masuda	9.9k	7.0k	4.4k	3.0k	1.7k	389	14.0k
Joohyuk Sohn	7.9k 0.8×	5.6k 0.8×	3.3k 0.7×	1.8k 0.6×	811 0.5×	303	10.9k
Joyce O’Shaughnessy	10.3k 1.0×	3.9k 0.6×	4.4k 1.0×	3.0k 1.0×	1.4k 0.8×	347	14.0k
Emilio Bajetta	10.4k 1.0×	5.8k 0.8×	3.7k 0.8×	3.9k 1.3×	1.6k 0.9×	325	16.6k
Luc Dirix	9.4k 0.9×	3.4k 0.5×	4.6k 1.0×	4.4k 1.5×	1.2k 0.7×	311	14.6k
Sabino De Placido	7.8k 0.8×	4.5k 0.6×	3.7k 0.8×	4.4k 1.5×	1.2k 0.7×	381	14.0k
Suzanne Kamel‐Reid	4.3k 0.4×	3.6k 0.5×	3.0k 0.7×	4.4k 1.5×	1.2k 0.7×	285	12.1k
Antonio Llombart‐Cussac	6.8k 0.7×	3.9k 0.6×	3.5k 0.8×	1.4k 0.5×	1.6k 0.9×	317	9.4k
Vivek Subbiah	6.0k 0.6×	4.6k 0.7×	3.1k 0.7×	3.7k 1.3×	706 0.4×	599	12.2k
Keyue Ding	8.1k 0.8×	8.4k 1.2×	2.6k 0.6×	3.4k 1.1×	641 0.4×	218	14.5k
Neal I. Lindeman	11.6k 1.2×	13.2k 1.9×	5.8k 1.3×	8.1k 2.7×	1.1k 0.6×	172	22.4k

Countries citing papers authored by Norikazu Masuda

Since Specialization

Citations

This map shows the geographic impact of Norikazu Masuda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Norikazu Masuda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Norikazu Masuda more than expected).

Fields of papers citing papers by Norikazu Masuda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Norikazu Masuda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Norikazu Masuda. The network helps show where Norikazu Masuda may publish in the future.

Co-authorship network of co-authors of Norikazu Masuda

This figure shows the co-authorship network connecting the top 25 collaborators of Norikazu Masuda. A scholar is included among the top collaborators of Norikazu Masuda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Norikazu Masuda. Norikazu Masuda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Honda, Maya, Masako Kataoka, Mami Iima, et al.. (2025). Institutional Variability in Ultrafast Breast MR Imaging: Comparing Compressed Sensing and View Sharing Techniques with Different Patient Populations and Contrast Injection Protocols. Magnetic Resonance in Medical Sciences. 24(4). n/a–n/a. 1 indexed citations

Naito, Yoichi, Seigo Nakamura, Nobuko Kawaguchi‐Sakita, et al.. (2024). Preliminary results from ASCENT-J02: a phase 1/2 study of sacituzumab govitecan in Japanese patients with advanced solid tumors. International Journal of Clinical Oncology. 29(11). 1684–1695. 4 indexed citations

Yamashita, Toshinari, Shigehira Saji, Toshimi Takano, et al.. (2024). Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).. Journal of Clinical Oncology. 42(16_suppl). 1007–1007. 2 indexed citations

Yoshinami, Tetsuhiro, Shigenori E. Nagai, Masaya Hattori, et al.. (2024). Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study. Breast Cancer. 31(4). 621–632. 2 indexed citations

Im, Seock‐Ah, Javier Cortés, David W. Cescon, et al.. (2024). Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC. npj Breast Cancer. 10(1). 79–79. 5 indexed citations

Futamura, Manabu, Takahiro Nakayama, Tetsuhiro Yoshinami, et al.. (2023). Detection of high-risk patients resistant to CDK4/6 inhibitors with hormone receptor-positive HER2-negative advanced and metastatic breast cancer in Japan (KBCSG-TR-1316). Breast Cancer. 30(6). 943–951. 2 indexed citations

Niikura, Naoki, Yuichiro Kikawa, Mari S. Oba, et al.. (2023). Fulvestrant plus palbociclib in advanced or metastatic hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer after fulvestrant monotherapy: Japan Breast Cancer Research Group-M07 (FUTURE trial). Breast Cancer Research and Treatment. 199(2). 253–263. 2 indexed citations

Cescon, David W., Peter Schmid, Hope S. Rugo, et al.. (2023). Health-related quality of life with pembrolizumab plus chemotherapy vs placebo plus chemotherapy for advanced triple-negative breast cancer: KEYNOTE-355. JNCI Journal of the National Cancer Institute. 116(5). 717–727. 7 indexed citations

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2023). OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. European Journal of Cancer. 184. 39–47. 54 indexed citations

10.

Masuda, Norikazu, et al.. (2022). Safety in Japanese Advanced Breast Cancer Patients Who Received Abemaciclib in MONARCH 2 and MONARCH 3: Assessment of Treatment-Emergent Neutropenia, Diarrhea, and Increased Alanine Aminotransferase and Aspartate Aminotransferase Levels. SHILAP Revista de lepidopterología. 8 indexed citations

11.

Ozaki, Yukinori, Junji Tsurutani, Toru Mukohara, et al.. (2022). Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B). European Journal of Cancer. 171. 193–202. 24 indexed citations

12.

Udagawa, Hibiki, Shunji Takahashi, Motohiro Hirao, et al.. (2022). Liposomal eribulin for advanced adenoid cystic carcinoma, gastric cancer, esophageal cancer, and small cell lung cancer. Cancer Medicine. 12(2). 1269–1278. 9 indexed citations

13.

Ozaki, Yukinori, Junji Tsurutani, Toru Mukohara, et al.. (2022). Data of programmed death-ligand 1 expression and VEGF: Nivolumab, bevacizumab and paclitaxel For HER2-negative metastatic breast cancer. Data in Brief. 45. 108558–108558. 1 indexed citations

14.

Masuda, Norikazu, Tetsuhiro Yoshinami, Masahiko Ikeda, et al.. (2021). Capecitabine in Combination with Endocrine Therapy as Maintenance Therapy after Bevacizumab Plus Paclitaxel Induction Therapy for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: KBCSG-TR1214. Cancers. 13(17). 4399–4399. 1 indexed citations

15.

Sato, Nobuaki, Norikazu Masuda, Takashi Morimoto, et al.. (2019). Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study. Cancer Medicine. 8(12). 5468–5481. 5 indexed citations

16.

Sato, Nobuaki, Norikazu Masuda, Takashi Morimoto, et al.. (2018). Neoadjuvant endocrine therapy with exemestane followed by response‐guided combination therapy with low‐dose cyclophosphamide in postmenopausal patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study. Cancer Medicine. 7(7). 3044–3056. 13 indexed citations

17.

Watanabe, Toru, Masaru Kuranami, Kenichi Inoue, et al.. (2017). Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study. Cancer. 123(5). 759–768. 28 indexed citations

18.

Watanabe, Junichiro, Yoshinori Ito, Toshiaki Saeki, et al.. (2017). Safety Evaluation of Trastuzumab Emtansine in Japanese Patients with HER2-Positive Advanced Breast Cancer. In Vivo. 31(3). 493–500. 18 indexed citations

19.

Robson, Mark E., Seock‐Ah Im, Elżbieta Senkus, et al.. (2017). Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine. 377(6). 523–533. 2156 indexed citations breakdown →

20.

Ogiya, Akiko, Rie Horii, Tadahiko Shien, et al.. (2016). Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer. Breast Cancer. 24(3). 473–482. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact